| 词条 | Lurasidone | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 释义 |
| IUPAC_name = (3aR,4S,7R,7aS)-2- | image = Lurasidone.svg | width = 270 | image2 = Lurasidone ball-and-stick based on xtal 2012.png | width2 = 250 | alt2 = Ball-and-stick model of the lurasidone molecule | pronounce = {{IPAc-en|lj|ʊəˈr|æ|s|ɪ|d|oʊ|n}} | tradename = Latuda, others | Drugs.com = {{drugs.com|monograph|lurasidone-hydrochloride}} | MedlinePlus = a611016 | DailyMedID = 88a244d1-eddb-499c-bee2-e1f49056e78f | licence_US = Lurasidone | pregnancy_AU = B1 | pregnancy_US = B | pregnancy_category = | licence_EU = yes | legal_AU = S4 | legal_CA = Rx-only | legal_US = Rx-only | legal_status = | routes_of_administration = By mouth | class = Atypical antipsychotic[1] | bioavailability = 9–19% (oral)[1] | protein_bound = ~99%[3] | metabolism = Liver (CYP3A4-mediated)[1] | elimination_half-life = 18–40 hours[1][3] | excretion = Faecal (67–80%), renal (9–19%)[1][3] | IUPHAR_ligand = 7461 | CAS_number = 367514-87-2 | ATC_prefix = N05 | ATC_suffix = AE05 | PubChem = 213046 | ChemSpiderID = 184739 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 22IC88528T | ChEMBL = 1237021 | ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI = 70735 | KEGG = D04820 | DrugBank = DB08815 | synonyms = SM-13,496 | C = 28 | H = 36 | N = 4 | O = 2 | S = 1 | molecular_weight = 492.68 g/mol | smiles = C1CC[C@H]([C@@H](C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)[C@H]6[C@@H]7CC[C@@H](C7)[C@H]6C5=O | StdInChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1 | StdInChIKey=PQXKDMSYBGKCJA-CVTJIBDQSA-N | melting_point = 176 | melting_high = 178 | solubility = 0.224 | specific_rotation = [α]20D −59° |drug_name=|alt=|caption=|type=}}Lurasidone, sold under the trade name Latuda among others, is an antipsychotic medication used to treat schizophrenia and bipolar disorder.[1] In bipolar it may be used together with a mood stabilizers such as lithium or valproate.[1] It is taken by mouth.[2] Common side effects include sleepiness, movement disorders, nausea, and diarrhea.[2] Serious side effects may include the potentially permanent movement disorder tardive dyskinesia, as well as neuroleptic malignant syndrome, an increased risk of suicide, angioedema, and high blood sugar levels.[2] In older people with psychosis as a result of dementia, it may increase the risk of dying.[2] Use during pregnancy is of unclear safety.[15] How it works is not clear but is believed to involve effects on dopamine and serotonin in the brain.[2] Lurasidone was approved for medical use in the United States in 2010.[2] A month supply in the United Kingdom costs the NHS about 90.72 £ as of 2019.[3] In the United States the wholesale cost of this amount is about 190.20 USD.[4] In 2016, it was the 227th most prescribed medication in the United States, with more than 2.2 million prescriptions.[5] Medical usesLurasidone is used for the treatment of schizophrenia and bipolar disorder.[2] In a 2013 study in a comparison of 15 antipsychotic drugs in effectiveness in treating schizophrenic symptoms, lurasidone demonstrated mild effectiveness. As effective as iloperidone, and 13 to 15% less effective than ziprasidone, chlorpromazine, and asenapine.[6] In July 2013 lurasidone received approval for bipolar I depression.[7][8] Few available atypical antipsychotics are known to possess antidepressant efficacy in bipolar disorder (with the notable exceptions being quetiapine,[9][10][11][12] olanzapine[13][14][15] and possibly asenapine[16]) as a monotherapy, even though the majority of atypical antipsychotics are known to possess significant antimanic activity,[17] which is yet to be clearly demonstrated for lurasidone. Lurasidone is not approved by the Food and Drug Administration (FDA) for the treatment of behavior disorders in older adults with dementia.[18] ContraindicationsLurasidone is contraindicated in individuals who are taking strong inhibitors of the liver enzyme CYP3A4 (ketoconazole, clarithromycin, ritonavir, levodropropizine, etc.) or inducers (carbamazepine, St. John's wort, phenytoin, rifampicin etc.).[19] The use of lurasidone in pregnant women has not been studied and is not recommended; in animal studies, no risks have been found.[20] Excretion in breast milk is also unknown; lurasidone is not recommended for breastfeeding women.[21] In the United States it is not indicated for use in children.[22] Side effects{{See also|List of adverse effects of lurasidone}}Side effects are generally similar to other antipsychotics. The drug has a relatively well-tolerated side effect profile, with low propensity for QTc interval changes, weight gain and lipid-related adverse effects.[23] In a 2013 meta-analysis of the efficacy and tolerability of 15 antipsychotic drugs it was found to produce the second least (after haloperidol) weight gain, the least QT interval prolongation, the fourth most extrapyramidal side effects (after haloperidol, zotepine and chlorpromazine) and the sixth least sedation (after paliperidone, sertindole, amisulpride, iloperidone and aripiprazole).[6] As with other atypical neuroleptics, lurasidone should be used with caution in the elderly because it puts them at an increased risk for a stroke or transient ischemic attack;[41][24] however, these risks are not likely to be greater than those associated with antipsychotics of other classes.[25] Similarly, lurasidone should not be used to treat dementia-related psychosis, as evidence has shown increased mortality with antipsychotic use.[26] Weight gain is reported in up to 15 and 16 percent of users.[27][28] InteractionsBlood plasma concentrations may be increased when combined with CYP3A4 inhibitors, possibly leading to more side effects. This has been clinically verified for ketoconazole, which increases lurasidone exposure by a factor of 9, and is also expected for other 3A4 inhibitors such as grapefruit juice. Co-administration of CYP3A4 inducers like rifampicin or St. John's wort can reduce plasma levels of lurasidone and its active metabolite, and consequently decrease the effects of the drug. For rifamipcin, the reduction was sixfold in a study.[3]PharmacologyPharmacodynamics{{See also|Atypical antipsychotic#Pharmacodynamics|Antipsychotic#Comparison of medications}}
Lurasidone acts as an antagonist of the dopamine D2 and D3 receptors, the serotonin 5-HT2A and 5-HT7 receptors, and the α2C-adrenergic receptor, and as a partial agonist of the serotonin 5-HT1A receptor.[31][30] It has only low and likely clinically unimportant affinity for the serotonin 5-HT2C receptor, which may underlie its low propensity for appetite stimulation and weight gain.[30][32][33] The drug also has negligible affinity for the histamine H1 receptor and the muscarinic acetylcholine receptors, and hence has no antihistamine or anticholinergic effects.[31][34] PharmacokineticsLurasidone is taken by mouth and has an estimated absorption rate of 9 to 19%.[1] Studies have shown that when lurasidone is taken with food, absorption increases about twofold. Peak blood plasma concentrations are reached after one to three hours. About 99% of the circulating substance are bound to plasma proteins.[38] Lurasidone is mainly metabolized in the liver via the enzyme CYP3A4, but has negligible affinity to other cytochrome P450 enzymes. It is transported by P-glycoprotein and ABCG2 and also inhibits these carrier proteins in vitro. It also inhibits the solute carrier protein SLC22A1, but no other relevant transporters.[38][39] Main metabolism pathways are oxidative N-dealkylation between the piperazine and cyclohexane rings, hydroxylation of the norbornane ring, and S-oxidation.[38][37]:59 Other pathways are hydroxylation of the cyclohexane ring and reductive cleavage of the isothiazole ring followed by S-methylation.[36] The two relevant active metabolites are the norbornane hydroxylation products called ID-14283 and ID-14326, the former reaching pharmacologically relevant blood plasma concentrations. The two major inactive metabolites are the N-dealkylation products (the carboxylic acid ID-20219 and the piperazine ID-11614[36]), and a norbornane hydroxylated derivative of ID-20219 (ID-20220). Of lurasidone and its metabolites circulating in the blood, the native drug makes up 11%, the main active metabolite 4%, and the inactive carboxylic acids 24% and 11%, respectively.[1][38] Several dozen metabolites have been identified altogether.[37]:59–61 Biological half-life is given as 18 hours or 20 to 40 hours in different sources. 80% or 67% of a radiolabelled dose was recovered from the faeces, and 9% or 19% from the urine.[1][38]HistoryLurasidone was made in 2003.[40] Lurasidone is a structural analogue of Ziprasidone (Zeldox). Lurasidone shows a very close pharmacological profile and has been synthesized similarly to Ziprasidone.[41] Lurasidone is chemically similar to Perospirone (also a chemical analogue of Zeldox), as well as Risperidone, Paliperidone and Iloperidone.[42] It has approval from the Food and Drug Administration (FDA) for treating schizophrenia since 2010 and for treating depressive episodes in adults with bipolar I disorder since 2013.[1] Society and cultureTrade namesIn India, this drug is available under the brand names of Atlura, Lurace, Lurafic, Luramax, Lurasid, Lurastar, Latuda, Lurata[43] and additionally as Alsiva, Emsidon, Lurakem, Luratrend, Tablura, and Unison.[44] Regulatory approvalLurasidone is approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia since 2010[45] and depressive episodes associated with bipolar I disorder since 2013.[7] It received regulatory approval in the United Kingdom in September 2014. In October 2014, NHS Scotland advised use of lurasidone for schizophrenic adults who have not seen improvements with previous antipsychotics due to problems that arise from weight gain or changes in metabolic pathways when taking other medications.[46] It received approval by the European Medicines Agency on 24 January 2014. It was launched in Canada for the treatment of schizophrenia in September 2012, Health Canada giving their Summary Basis of Decision (SBD) as favourable on 15 October 2012.[47] European Commission has granted a marketing authorization for once-daily oral lurasidone for the treatment of schizophrenia in adults.[48] It is approved for use in the EU.[49] See also
References1. ^1 2 3 4 5 6 7 {{cite web|title=Product information Latuda (lurasidone hydrochloride)|work=TGA eBusiness Services|publisher=Therapeutic Goods Administration|date=16 April 2014|access-date=1 May 2014|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2014-PI-01715-1|format=PDF}} 2. ^1 2 3 4 5 6 7 8 9 {{cite web |title=Lurasidone Hydrochloride Monograph for Professionals |url=https://www.drugs.com/monograph/lurasidone-hydrochloride.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists |accessdate=21 March 2019 |language=en}} 3. ^1 {{cite book|title=British national formulary : BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|pages=393-394|edition=76}} 4. ^{{cite web |title=NADAC as of 2019-02-27 |url=https://data.medicaid.gov/Drug-Pricing-and-Payment/NADAC-as-of-2019-02-27/s7c9-pfa6 |website=Centers for Medicare and Medicaid Services |accessdate=3 March 2019 |language=en}} 5. ^{{cite web |title=The Top 300 of 2019 |url=https://clincalc.com/DrugStats/Top300Drugs.aspx |website=clincalc.com |accessdate=26 February 2019}} 6. ^1 {{cite journal | vauthors = Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM | title = Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis | journal = Lancet | volume = 382 | issue = 9896 | pages = 951–62 | date = September 2013 | pmid = 23810019 | doi = 10.1016/S0140-6736(13)60733-3 }} 7. ^1 {{cite web | vauthors = Lowes R | title = Lurasidone Approved for Bipolar Depression | work = Medscape | date = 2013 | url = http://www.medscape.com/viewarticle/807204 }} 8. ^{{cite journal | vauthors = Bawa R, Scarff JR | title = Lurasidone: a new treatment option for bipolar depression-a review | journal = Innovations in Clinical Neuroscience | volume = 12 | issue = 1–2 | pages = 21–3 | date = 2015 | pmid = 25852975 | pmc = 4382136 }} 9. ^{{cite journal | vauthors = Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, Brecher M | title = A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I) | journal = The Journal of Clinical Psychiatry | volume = 71 | issue = 2 | pages = 150–62 | date = February 2010 | pmid = 20122369 | doi = 10.4088/JCP.08m04995gre | collaboration = EMBOLDEN I (Trial 001) Investigators }} 10. ^{{cite journal | vauthors = Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D | title = Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression | journal = Journal of Affective Disorders | volume = 121 | issue = 1–2 | pages = 106–15 | date = February 2010 | pmid = 19903574 | doi = 10.1016/j.jad.2009.10.007 }} 11. ^{{cite journal |doi=10.1111/j.1399-5618.2008.00585.x |title=Corrigendum |year=2008 |journal= Bipolar Disorders |volume=10 |issue=3 |pages= 451}} 12. ^{{cite journal | vauthors = Thase ME | title = Quetiapine monotherapy for bipolar depression | journal = Neuropsychiatric Disease and Treatment | volume = 4 | issue = 1 | pages = 11–21 | date = February 2008 | pmid = 18728771 | pmc = 2515925 | doi = 10.2147/ndt.s1162 }} 13. ^{{cite journal | vauthors = Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A | title = Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression | journal = Archives of General Psychiatry | volume = 60 | issue = 11 | pages = 1079–88 | date = November 2003 | pmid = 14609883 | doi = 10.1001/archpsyc.60.11.1079 }} 14. ^{{cite journal | vauthors = Tohen M, Katagiri H, Fujikoshi S, Kanba S | title = Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies | journal = Journal of Affective Disorders | volume = 149 | issue = 1–3 | pages = 196–201 | date = July 2013 | pmid = 23485111 | doi = 10.1016/j.jad.2013.01.022 }} 15. ^{{cite journal | vauthors = Corya SA, Perlis RH, Keck PE, Lin DY, Case MG, Williamson DJ, Tohen MF | title = A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression | journal = The Journal of Clinical Psychiatry | volume = 67 | issue = 5 | pages = 798–806 | date = May 2006 | pmid = 16841630 | doi = 10.4088/JCP.v67n0514 }} 16. ^{{cite journal |vauthors = Azorin JM, Sapin C, Weiller E | title = Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses | journal = Journal of Affective Disorders | volume = 145 | issue = 1 | pages = 62–9 | date = February 2013 | pmid = 22868059 | doi = 10.1016/j.jad.2012.07.013 }} 17. ^{{cite journal | vauthors = Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M, Spineli LM, Goodwin GM, Geddes JR | title = Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis | journal = Lancet | volume = 378 | issue = 9799 | pages = 1306–15 | date = October 2011 | pmid = 21851976 | doi = 10.1016/S0140-6736(11)60873-8 }} 18. ^{{Cite web|url=https://medlineplus.gov/druginfo/meds/a611016.html|title=Lurasidone: MedlinePlus Drug Information |website= medlineplus.gov| language=en|access-date= 2018-09-11}} 19. ^{{cite journal | vauthors = Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A | title = Lurasidone drug-drug interaction studies: a comprehensive review | journal = Drug Metabolism and Drug Interactions | volume = 29 | issue = 3 | pages = 191–202 | year = 2014 | pmid = 24825095 | doi = 10.1515/dmdi-2014-0005 }} 20. ^Pregnancy category 21. ^{{cite journal | title = ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation | journal = Obstetrics and Gynecology | volume = 111 | issue = 4 | pages = 1001–20 | date = April 2008 | pmid = 18378767 | doi = 10.1097/AOG.0b013e31816fd910 | author1 = ACOG Committee on Practice Bulletins--Obstetrics }} 22. ^{{cite journal | vauthors = Moore TA | title = Schizophrenia treatment guidelines in the United States | journal = Clinical Schizophrenia & Related Psychoses | volume = 5 | issue = 1 | pages = 40–9 | date = April 2011 | pmid = 21459738 | doi = 10.3371/CSRP.5.1.6 }} 23. ^{{cite press release |title=Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study |publisher=Dainippon Sumitomo Pharma |date=Aug 26, 2009 |url=http://www.ds-pharma.com/pdf_view.php?id=170 |access-date=October 3, 2016 }} 24. ^{{cite web|url=https://www.drugs.com/latuda.html|publisher=Drugs.com|title=Latuda|access-date=2010-12-17}} 25. ^{{cite journal | vauthors = Herrmann N, Mamdani M, Lanctôt KL | title = Atypical antipsychotics and risk of cerebrovascular accidents | journal = The American Journal of Psychiatry | volume = 161 | issue = 6 | pages = 1113–5 | date = June 2004 | pmid = 15169702 | doi = 10.1176/appi.ajp.161.6.1113 }} 26. ^{{cite web|last=Sunovion Pharmaceuticals|title=Latuda Prescribing Information|url=http://www.latuda.com/LatudaPrescribingInformation.pdf|work=Latuda.com|access-date=25 March 2014}} 27. ^{{cite journal | vauthors = Meyer JM, Mao Y, Pikalov A, Cucchiaro J, Loebel A | title = Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia | journal = International Clinical Psychopharmacology | volume = 30 | issue = 6 | pages = 342–50 | date = November 2015 | pmid = 26196189 | pmc = 4593468 | doi = 10.1097/YIC.0000000000000091 }} 28. ^{{cite journal | vauthors = Ketter TA, Sarma K, Silva R, Kroger H, Cucchiaro J, Loebel A | title = Lurasidone in the long-term treatment of patients with bipolar disorder: A 24-week open-label extension study | journal = Depression and Anxiety | volume = 33 | issue = 5 | pages = 424–34 | date = May 2016 | pmid = 26918425 | pmc = 5069590 | doi = 10.1002/da.22479 | laysummary = http://www.jwatch.org/na40667/2016/03/14/lurasidone-long-term-treatment-bipolar-depression | laydate = March 14, 2016 | laysource = NEJM Journal Watch }} 29. ^{{cite web | title = PDSP Ki Database | work = Psychoactive Drug Screening Program (PDSP) | vauthors = Roth BL, Driscol J | publisher = University of North Carolina at Chapel Hill and the United States National Institute of Mental Health | format = HTML | access-date = 14 August 2017 | url = https://pdsp.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=lurasidone&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query}} 30. ^1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 {{cite journal | vauthors = Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M | title = Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 334 | issue = 1 | pages = 171–81 | date = July 2010 | pmid = 20404009 | doi = 10.1124/jpet.110.167346 }} 31. ^1 {{cite journal | vauthors = Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y | title = Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test | journal = European Journal of Pharmacology | volume = 572 | issue = 2–3 | pages = 160–70 | date = October 2007 | pmid = 17662268 | doi = 10.1016/j.ejphar.2007.06.058 }} 32. ^{{cite journal | vauthors = Samalin L, Ben Gharbia M, Garnier M, Llorca PM | title = [Short-term efficacy and safety of lurasidone in the treatment of schizophrenia] | language = French | journal = L'Encephale | volume = 40 | issue = 6 | pages = 507–17 | date = December 2014 | pmid = 25453735 | doi = 10.1016/j.encep.2014.10.009 | trans-title = Short-term efficacy and safety of lurasidone in the treatment of schizophrenia }} 33. ^{{cite journal |last1=Lincoln |first1=Jana |last2=Tripathi |first2=Aveekshit | name-list-format = vanc |year=2011 |title=Lurasidone for Schizophrenia |journal=Current Psychiatry |volume=10 |issue=1 |pages=67–70 |url=http://www.mdedge.com/currentpsychiatry/article/64162/schizophrenia-other-psychotic-disorders/lurasidone-schizophrenia}} 34. ^{{cite journal | vauthors = Greenberg WM, Citrome L | title = Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature | journal = Clinical Pharmacokinetics | volume = 56 | issue = 5 | pages = 493–503 | date = May 2017 | pmid = 27722855 | doi = 10.1007/s40262-016-0465-5 }} 35. ^{{cite journal | vauthors = Katteboina MY, Pilli NR, Mullangi R, Seelam RR, Satla SR | title = LC-MS/MS assay for the determination of lurasidone and its active metabolite, ID-14283 in human plasma and its application to a clinical pharmacokinetic study | journal = Biomedical Chromatography | volume = 30 | issue = 7 | pages = 1065–1074 | date = July 2016 | pmid = 26577488 | doi = 10.1002/bmc.3651 | url = https://www.researchgate.net/publication/284172622 }} 36. ^1 2 3 {{cite journal | vauthors = Caccia S, Pasina L, Nobili A | title = Critical appraisal of lurasidone in the management of schizophrenia | journal = Neuropsychiatric Disease and Treatment | volume = 8 | pages = 155–68 | year = 2012 | pmid = 22570547 | pmc = 3346058 | doi = 10.2147/NDT.S18059 }} 37. ^1 2 {{cite web|url=http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200603Orig1s000PharmR.pdf|title=Lurasidone pharmacology review|publisher=Center for Drug Evaluation and Research|date=30 December 2009}} 38. ^1 2 3 4 5 6 7 8 {{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002713/WC500164683.pdf|title=Latuda: EPAR – Product Information|publisher=European Medicines Agency|date=14 April 2016}} 39. ^1 {{cite web|url=http://psychotherapeuticdrugs.com/index.php/new-drug-approvals/latuda-lurasidone-hcl|title=Latuda: Prescribing Information|publisher=Psychotherapeutic Drugs|access-date=2010-12-17}} 40. ^{{cite web|url=http://www.mmm-online.com/features/leading-latuda-through-the-crowd/article/213096/|title=Leading Latuda through the crowd|date=1 October 2011|publisher=}} 41. ^{{Cite book|url=https://books.google.com/books?id=A8oHBgAAQBAJ&pg=PA100&lpg=PA100&dq#v=onepage&q&f=false|title=Synthesis of Best-Seller Drugs|first1=Ruben|last1=Vardanyan|first2=Victor|last2=Hruby | name-list-format = vanc |date=7 January 2016|publisher=Academic Press|via=Google Books|isbn=9780124115248}} 42. ^{{cite web|url=https://web.archive.org/web/20161117142131/http://excli.de/vol13/Mauri_13102014_proof.pdf|title=Wayback Machine|date=17 November 2016|publisher=}} 43. ^{{Cite web|url=http://www.mims.com/india/drug/search?q=Lurasidone|title='Lurasidone' drug search |last=|first=|date=|publisher=CIMS India|archive-url=|archive-date=|dead-url=|access-date=2018-04-21}} 44. ^{{Cite web|url=https://www.ndrugs.com/?s=lurasidone#substitutes|title=Generic Drugs (ndrugs.com)|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=2018-04-30}} 45. ^{{cite press release | title = FDA approves Latuda to treat schizophrenia in adults | publisher = USFDA | date = 2010-10-28 | url = http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm231512.htm | access-date = October 29, 2010}} 46. ^{{cite web|publisher= Scottish Medicines Consortium|year=2014|title=Lurasidone, 18.5mg, 37mg, 74mg film-coated tablets (Latuda) SMC No. (994/14)|url= http://www.scottishmedicines.org.uk/files/advice/lurasidone__Latuda__FINAL_Sept_2014_amended_15.09.14_for_website.pdf | work= scottishmedicines.org.uk}} 47. ^{{cite web|url= http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2012_latuda_145406-eng.php#a2| work= hc-sc.gc.ca |publisher= Health Canada|title=Summary Basis of Decision (SBD) for Latuda|year=2012}} 48. ^{{cite web|url=http://www.tpi.takeda.com/media/news-releases/2014/european-marketing-authorization-for-latuda/|title=European Marketing Authorization for Latuda|work=takeda.com|access-date=25 November 2015}} 49. ^{{cite web|url=http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002713/human_med_001737.jsp&mid=WC0b01ac058001d124| publisher= European Medicines Agency | title= Latuda|work=europa.eu|access-date=25 November 2015}} External links
| title = Pharmacodynamics | titlestyle = background:#ccccff | list1 ={{Adrenergic receptor modulators}}{{Dopamine receptor modulators}}{{Serotonin receptor modulators}} }} 11 : 2010 introductions|Antidepressants|Atypical antipsychotics|Benzoisothiazoles|Heterocyclic compounds (bridged-ring)|Imides|Isoindolines|Lactams|Mood stabilizers|Piperazines|RTT |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 随便看 |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。